ArticleOncogene2021
Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer.
Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Immune Cytolytic Activity Correlates with Tumor Microenvironmental Aberrations in Colorectal Cancer.International journal of molecular sciences · 2026Article
- 5-HT reuptake blockade induces pyroptosis in BRAFCell reports. Medicine · 2026Article
- FKH domain-mediated nuclear FOXP3 suppresses gastric cancer malignancy via c-MYC/CDKN1A regulation, EMT inhibition, and PI3K/AKT signaling modulation.Molecular and cellular biochemistry · 2026Article
- Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA.Discover oncology · 2025Article
- Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy.British journal of cancer · 2025Article
- A high stroma-tumor ratio is associated with an immunosuppressive tumor microenvironment and a poor prognosis in bladder cancer.Frontiers in oncology · 2025Article
- NIFK, a Potential Prognostic and Immunological Biomarker in Pan-Cancer Analysis, Significantly Regulates Proliferation and Metastasis of Colorectal Cancer.Recent patents on anti-cancer drug discovery · 2025Article
- Ferroptosis and the tumor microenvironment.Journal of experimental & clinical cancer research : CR · 2024Review
- Increases in 4-Acetaminobutyric Acid Generated by Phosphomevalonate Kinase Suppress CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Distinctive multicellular immunosuppressive hubs confer different intervention strategies for left- and right-sided colon cancers.Cell reports. Medicine · 2024Article
- Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies.Frontiers in immunology · 2024Review
- Palmitoylation landscapes across human cancers reveal a role of palmitoylation in tumorigenesis.Journal of translational medicine · 2023Article
- The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer.British journal of cancer · 2023Article
- Infiltration of a Unique CD8Journal of hepatocellular carcinoma · 2023Article
- c-Myc-IMPDH1/2 axis promotes tumourigenesis by regulating GTP metabolic reprogramming.Clinical and translational medicine · 2023Article
- A novel high-risk subpopulation identified by CTSL and ZBTB7B in gastric cancer.British journal of cancer · 2022Article
- Ferroptosis-Associated Molecular Features to Aid Patient Clinical Prognosis and Therapy Across Human Cancers.Frontiers in immunology · 2022Article
- FOXP family DNA methylation correlates with immune infiltration and prognostic value in NSCLC.Frontiers in genetics · 2022Article
- Comprehensive Characterization of Integrin Subunit Genes in Human Cancers.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is characterized by a heterogeneous tumor microenvironment (TME) that regulates cancer progression and therapeutic response. Overexpression of FOXP3 and CTLA4 is associated with immunosuppressive TME and poor prognosis in many cancer types. However, opposite results were reported in CRC. Thus, we performed comprehensive analyses to evaluate the exact prognostic value of FOXP3 and CTLA4 in CRC. Here, the expression levels of FOXP3 and CTLA4 were used to construct a subtyping system based on >1200 CRC patients from multiple independent public datasets. We revealed that, in CRC patients with relatively high expression of FOXP3, there exist two different subpopulations with opposite survival patterns according to CLTA4 expression. We further established a method for evaluating all cohorts and identified a novel FOXP3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.